Effects of Cerebral Microbleeds on the Incidence of Cerebral Events in Patients with Ischemic Cerebrovas-cular Disease at the Last Stage of Antiplatelet Agent
10.6039/j.issn.1001-0408.2016.17.19
- VernacularTitle:是否伴发脑微出血对缺血性脑血管病患者应用抗血小板药后期脑血管事件发生率影响的临床分析Δ
- Author:
Chunjie LIU
;
Hailiang ZHENG
;
Xiaoqing LI
- Publication Type:Journal Article
- Keywords:
Antiplatelet agent;
Ischemic cerebrovascular disease;
Cerebral microbleeds;
Cerebral event
- From:
China Pharmacy
2016;27(17):2361-2363
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the incidence of cerebral events in patients with ischemic cerebrovascular disease compli-cating with cerebral microbleeds(CMBs)at the last stage of antiplatelet agent use. METHODS:140 patients with ischemic cerebro-vascular disease were selected from Beijing Anzhen Hospital Affilicated to Capital Medical University during Jan. 2013-Jan. 2014, and then divided into CMBs group and non-CMBs group according to whether complicated with CMBs,with 70 cases in each group. After followed up for 1 year(regular use of aspirin 100 mg/d and/or clopidogrel 75 mg/d),the incidence of recurrent cere-bral infarction and cerebral bleeding and mortality were compared. RESUTLS:The incidence of recurrent cerebral infarction was 12.9% in CMBs group and 8.6% in non-CMBs group,without statistical significance(P=0.412);the incidence of cerebral bleed-ing was 10.0% in CMBs group and 1.4% in non-CMBs group,with statistical significance(P=0.029);the mortality of cerebro-vascular event at the last stage was 5.7% in CMBs group and 4.3% in non-CMBs group,without statistical significance (P=0.698). CONCLUSIONS:The risk of cerebral bleeding increase in patients with ischemic cerebrovascular disease complicating with CMBs after the application of antiplatelet agent. For patients with ischemic cerebrovascular disease complicating with CMBs,the application of antiplatelet agent should be based on the complete judgment and weighing of benefit and bleeding risk.
